| BCBS Montana Medical Policies | Remdesivir | 2026-07-01 |
| BCBS Montana Medical Policies | Tezepelumab-ekko | 2026-07-01 |
| BCBS Montana Medical Policies | Ustekinumab and Associated Biosimilars | 2026-07-01 |
| Medical Mutual | Enhanced Oncology Value (Intravenous) (EOV) | 2026-07-01 |
| Medical Mutual | Enhanced Oncology Value: Opdualag™ (nivolumab/relatlimab-rmbw) (Intravenous) (EOV) | 2026-07-01 |
| BCBS Florida Coverage Guidelines | Transthyretin Amyloidosis (ATTR) (09-J5000-50) | 2026-07-01 |
| BCBS Florida Coverage Guidelines | Interleukin-5 (IL-5) Inhibitors (09-J5000-35) | 2026-07-01 |
| BCBS Florida Coverage Guidelines | Interleukin 13 (IL-13) Antagonists (09-J5000-37) | 2026-07-01 |
| BCBS Florida Coverage Guidelines | Lupus (09-J5000-51) | 2026-07-01 |
| HealthPartners | Specialty testing: toxicology & pharmacogenomics – | 2026-07-01 |